Evidence map›Paper›PMID 38878125›Full record

ArticleBreast cancer research and treatment2024

Pedigree analysis exploring the inconsistency between diverse phenotypes and testing criteria for germline TP53 mutations in Chinese women with breast cancer.

Xin Huang, Chang Chen, Yan Lin, Changjun Wang, Xingtong Zhou, Ying Xu, Qiang Sun, Yidong Zhou

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xin Huang *Department of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Chang Chen *Department of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Yan LinDepartment of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Changjun WangDepartment of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Xingtong ZhouDepartment of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Ying XuDepartment of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Qiang SunDepartment of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
Yidong ZhouDepartment of Breast Surgery, Peking Union Medical College Hospital, Beijing, China. zhouydpumch@126.com.ORCID http://orcid.org/0000-0001-6741-007X

Funding

CAMS Innovation Fund for Medical Sciences 2023-I2M-C&T-B-015China Medical Board Open Competition Grants 21-421the National High Level Hospital Clinical Research Funding 2022-PUMCH-B-039
6 · The paper itself

Abstract

purposeIn the present study, we addressed the inconsistency between the testing criteria and diverse phenotypes for germline TP53 mutation in patients with breast cancer in the Chinese population.

methodWe proposed a new added item (synchronous or metachronous bilateral breast cancer) as one of the testing criteria (aimed at high-penetrance breast cancer susceptibility genes) and applied it for determining TP53 germline mutation status in 420 female patients with breast cancer using multigene panel-based next-generation sequencing, Sanger sequencing, and mass spectrometry.

resultsWe found that 1.4% of patients carried a pathogenic or likely pathogenic germline TP53 mutation. Compared with BRCA mutation carriers (8.0%) and non-carriers (7.1%), TP53 mutation carriers (33.3%) developed breast cancer earlier. The majority of TP53 mutation carriers (66.7%) developed breast cancer after age 30 and had bilateral breast cancer (33.3%). Pedigree investigation of four TP53 carriers and a patient with a TP53 variant of unknown significance revealed that neither of their parents harbored the same mutations as the probands, indicating that the mutations might occur de novo.

conclusionOur study revealed distinguishing features of TP53 carriers among Chinese women with breast cancer, which is inconsistent with the currently used testing criteria; therefore, the newly proposed testing criteria may be more appropriate.

Indexed as

Breast NeoplasmsGenetic Predisposition to DiseaseGerm-Line MutationTumor Suppressor Protein p53AdultAgedChinaEast Asian PeopleFemaleGenetic TestingHigh-Throughput Nucleotide SequencingHumansMiddle AgedPedigreePhenotypeTP53 protein, humanTumor Suppressor Protein p53Breast cancerDe novo mutationMosaic mutationPedigree analysisPhenotypeTP53 mutation

Identifiers

PMID38878125
PMCPMC11208215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.